Tuojie Biotech (Shanghai) Co. Ltd. has divulged cyclin-dependent kinase 2 (CDK2)/cyclin E inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Uppthera Inc. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding agent coupled to serine/threonine-protein kinase PLK1 (STPK13) targeting moiety through a linker, acting as novel PLK1 protein degradation-inducing compounds with use for the treatment of cancer and neurological disorders.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Wuhan Institute of Virology of the Chinese Academy of Sciences have synthesized amide compounds reported to be useful for the treatment of dengue virus infection, skin inflammation, inflammatory joint disease, inflammatory bowel disease and autoimmune disease.
Blueprint Medicines Corp. has disclosed EGFR (L858R/T790M/C797S triple mutant) and/or EGFR (exon 19 deletion mutant) inhibitors reported to be useful for the treatment of cancer.
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co. Ltd. has described pyrimidine and nitrogen-containing 6-membered aromatic heterocyclic compounds acting as S-adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has divulged 1,2,4-triazole compounds acting as tyrosine-protein kinase receptor UFO (AXL) inhibitors reported to be useful for the treatment of cancer.
The Consejo Superior de Investigaciones Cientificas (CSIC) has identified chemokine CXCR4 (SDF-1 receptor) receptor ligands reported to be useful for the treatment of cancer, rheumatoid arthritis and AIDS.
Sichuan Huiyu Pharmaceutical Co. Ltd. and Sichuan Huiyu Seacross Pharma Technology Ltd. have disclosed derivatives with pyrimidine-fused cyclic structures acting as son of sevenless homolog 1 (SOS1) inhibitors reported to be useful for the treatment of cancer, cardiofaciocutaneous and Noonan syndromes.
RSS